MiraDX is a biotech company based in Los Angeles, CA, specializing in the development of personalized cancer treatments and drug development using unique microRNA-based biomarkers.
Their innovative tests, such as the PROSTOXTM Test, help prostate cancer patients avoid radiation toxicity, while their KRAS-Variant Test provides critical information for estrogen management and cancer screening in women. MiraDX is also creating biomarker panels, like the PrevIOTOX Test, to predict toxicity and response to immunotherapies, making significant strides towards personalizing radiotherapy and improving patient outcomes.
Generated from the website